Company Overview and News
THIS week has not been great for stocks. The Dow Jones and S&P 500 have had six consecutive days of straight declines with big plunges on Wednesday and Thursday.
5014 5222 CIMDF 1023 5347 5225 TNABY 6888 MYPRY AXXTF TNABF Q0F IHHHF
KUALA LUMPUR (Sept 20): Felda Global Ventures Holdings Bhd's (FGV) largest shareholder Federal Land Development Authority (FELDA) said it hopes for its unit to turnaround as soon as possible, particularly within the next six months to one year.
PORT KLANG, Sept 13 — President and Chief Executive Officer (CEO) of Felda Global Ventures Holdings Bhd (FGV), Datuk Zakaria Arshad, today refuted claims that he has been fired as member of the board of directors of the agro-based company.
KUALA LUMPUR: FGV Holdings Bhd, formerly known as the Felda Global Ventures Holdings Bhd, has appointed former Bursa Malaysia Bhd chief executive officer (CEO) Datuk Yusli Mohamed Yusoff and Datin Hoi Lai Ping to its board of directors.
BSMAF 5222 1818
KUALA LUMPUR (Sept 6): FGV Holdings Bhd, formerly known as the Felda Global Ventures Holdings Bhd, has appointed former Bursa Malaysia Bhd chief executive officer Datuk Yusli Mohamed Yusoff, and Datin Hoi Lai Ping to its board.
BSMAF 5222 1818
KUALA LUMPUR (Aug 28): FGV Holdings Bhd slipped into the red in the second quarter ended June 30, 2018 (2QFY18), with a net loss of RM23.23 million, compared with a net profit of RM37.26 million a year ago.
BSMAF 5222 1818
KUALA LUMPUR (Aug 28): FGV Holdings Bhd revealed yesterday that forensic investigations into six transactions and investment decisions undertaken previously had exposed the group to significant financial loss.
BSMAF 5222 1818
Asset disposal: Workers unload oil palm fruits from a lorry at a Felda factory in Trolak, Perak. Strengthening the agency’s cashflow position will likely include the disposal of non-strategic assets such as properties, both locally and abroad, as well as other non-performing businesses.
KUALA LUMPUR (Aug 2): The Center to Combat Corruption and Cronyism (C4) has called for appointments to the board of Khazanah Nasional Bhd to be done by a committee, to ensure cronyism is avoided.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...